79.00
+1.35(+1.74%)
Currency In USD
| Previous Close | 77.65 |
| Open | 77.84 |
| Day High | 79.99 |
| Day Low | 77.39 |
| 52-Week High | 80.99 |
| 52-Week Low | 26.2 |
| Volume | 664,605 |
| Average Volume | 862,806 |
| Market Cap | 4.33B |
| PE | -18.04 |
| EPS | -4.38 |
| Moving Average 50 Days | 70.22 |
| Moving Average 200 Days | 47.47 |
| Change | 1.35 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $3,721.15 as of January 14, 2026 at a share price of $79. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 2 years ago, it would be worth $2,425.54 as of January 14, 2026 at a share price of $79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
GlobeNewswire Inc.
Jan 06, 2026 11:00 AM GMT
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
GlobeNewswire Inc.
Jan 05, 2026 9:01 PM GMT
Webcast to be held Tuesday, January 6th at 8:00 a.m. ETSAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing Results support developme